IDO1 and neoplasm: Targets of IFN-γ signalling in the tumour microenvironment (TME) release additional molecules such as indoleamine 2,3-dioxygenase 1 (IDO1)7 that may serve as an additional brake on chronic T cell activation to restore immune host balance and prevent tissue pathology.8